3800 points "tug-of-war" portfolio adjustment is timely! Is the medical device sector "relay" rally coming soon?

This week, the major A-shares started doing “sit-ups” at 3,800 points. Sector rotation has accelerated significantly, with a clear example being the continuous surge in semiconductor equipment, which directly pushed down the previously hot “CPO.” Many sectors still at low levels have fundamentally changed, making it worthwhile to adjust positions—such as the medical devices sector, which has already begun to “move.”

The 11th batch of centralized procurement was just officially announced, with comprehensive rule optimizations and clear signals of “anti-inflation.” The fundamentals of the medical devices sector are accelerating their recovery, and the market shows strong potential for continued growth. Currently, the Medical Devices Index ETF (159898) has been attracting 27 million yuan for three consecutive days, accumulating over 100 million yuan in the past 20 days, with a slight intraday increase of 0.34% today.

This momentum is promising.

Many friends may wonder why funds are choosing to buy medical devices at the bottom. Simply put, under the resonance of policy support, performance recovery, and international expansion dividends, the upward channel for medical devices is opening, making now a good time to position.

1. Policy Strength: From “Price Competition” to “Innovation Competition”

First, the biggest news in the pharmaceutical sector these days is the new approach in the 11th batch of national centralized procurement—“Stabilize clinical, ensure quality, prevent collusion, and fight internal competition.” The procurement process started on October 21, with clear optimization of price difference control to prevent “bad money driving out good,” which will undoubtedly serve as a major catalyst for the sector.

For example:

A certain cardiac stent was priced at 13,000 yuan before procurement, but after the process, it dropped to 700 yuan. While patients benefit, company profits are squeezed, and innovation motivation diminishes. Now, the policy shifts toward “ensuring quality + encouraging innovation,” allowing medical device companies to free up profit margins for R&D. High-end imaging equipment, surgical robots, and AI-assisted diagnostics—these “hard technologies”—are directly benefiting.

2. Performance Recovery: From “Darkest Hour” to “Turning Point Upward”

Wind data shows that by 2025, the CSI Medical Devices Index is expected to achieve a net profit attributable to parent company of 41.983 billion yuan, with a year-on-year growth rate of +23.71%! Remember, in 2023, industry profits were still negative, but the sector has clearly passed the “darkest hour.”

More importantly, from the second half of this year into next year, policies will continue to “support”: centralized procurement will no longer focus solely on low prices, the approval process for innovative drugs and devices will accelerate into medical insurance, and equipment renewal loans with interest subsidies will be available. In simple terms, medical device companies now have both profit and direction to compete, making a performance rebound highly probable.

3. Going Global: From “Made in China” to “Global Brands”

If policy and performance are the “internal strength,” then going overseas is the “external extension” for medical devices. Today, Chinese medical device innovation is no longer “knockoffs”—United Imaging’s MRI machines are sold in the US, Mindray’s monitors hold 70% of the European market, and Nanjing Micro Medical’s endoscope consumables are standard in German hospitals… By 2025, many device companies’ overseas business growth rates will surpass domestic, with international revenue even overtaking domestic.

Leading companies in various medical device sectors are experiencing higher overseas growth in the first half of 2025 than domestically.

Source: Company announcements, Wind, Guojin Securities Research Institute

It can be said that Chinese medical device companies have vast growth potential globally, and their valuations are gradually aligning with innovative US-listed medical device companies, offering significant room for expansion.

Recently, the Medical Devices Index ETF (159898) has been a strong choice for those布局ing in medical devices, as its underlying index comprehensively covers leading companies in the ChiNext and STAR Market segments, with combined weights exceeding 80%. It’s suitable for holding during current narrow-range fluctuations, preparing for the next major rally.

Author: ETF Golden Shovel

(Edited by: Liu Jing HZ010)

【Disclaimer】This article reflects only the author’s personal opinions and is not related to Hexun.com. Hexun maintains neutrality regarding the statements and opinions in this article and does not guarantee the accuracy, reliability, or completeness of the content. Readers should use it as a reference and bear all responsibilities themselves. Email: news_center@staff.hexun.com